Intensification Through Process Simplification: A Disruptive, Scalable, and Robust Capture Solution with Sartobind^® Rapid A

Monoclonal antibodies (mAbs) are an extremely successful class of therapeutic agents for a wide range of diseases. Improving and scaling their production to be able to produce larger quantities more cost effectively is an important goal for the pharmaceutical industry. There are several hurdles to scaling a mAb production process that must be overcome. These challenges are also coupled with an industry trend towards orphan drugs and more personalized medicine, which allows production plants to become multiproduct facilities to increase the overall throughput of the facility.

To realize the opportunities provided by a multiproduct facility, new production solutions are required to accommodate all scales in a flexible way. Utilizing packed bed columns for mAb capture requires a large footprint, which impacts the overall facility design and floor space utilization. Membrane chromatography technologies such as Sartobind^® Rapid A provide an exciting new path towards scalability with shorter cycle times and a smaller production footprint. Considering alternative technologies to those currently in use may be attractive, however their implementation requires very close alignment with PD and procurement. In this white paper, we discuss what process adjustment considerations need to be made and how Sartobind^® Rapid A improves productivity.